Drug
Usnoflast
Usnoflast: highest development phase Phase 2, developed by Zydus. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Zydus
Trials
| Drug | Phase | Indication |
|---|---|---|
| 50 mg Usnoflast NCT07023835 | Phase 2 | Amyotrophic Lateral Sclerosis (ALS) |
Latest
No recent events.
Follow Usnoflast on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.